

**See “Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis” on page 115-118.**

**Supplementary Table 1.** Adverse Events during Tofacitinib Administration

Variable	No. (%) (n = 30)
Infectious adverse events	9 (30.0)
Herpes zoster	3 (10.0)
Upper respiratory tract infection	2 (6.7)
Paranasal sinusitis	2 (6.7)
External otitis	1 (3.3)
Serpigo	1 (3.3)
Dyslipidemia	4 (13.3)
Acne	1 (3.3)
Serious adverse events	0